Sumitomo Mitsui Trust Holdings Inc. Has $41.64 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sumitomo Mitsui Trust Holdings Inc. decreased its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 4.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,320,652 shares of the biotechnology company's stock after selling 67,922 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned about 4.94% of Arcturus Therapeutics worth $41,640,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. New York State Teachers Retirement System acquired a new stake in Arcturus Therapeutics in the 3rd quarter valued at about $53,000. Great West Life Assurance Co. Can boosted its stake in Arcturus Therapeutics by 29.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 2,679 shares of the biotechnology company's stock worth $64,000 after buying an additional 616 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in Arcturus Therapeutics by 63.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 5,043 shares of the biotechnology company's stock valued at $79,000 after buying an additional 1,956 shares during the period. Point72 Middle East FZE acquired a new position in shares of Arcturus Therapeutics during the 4th quarter valued at about $79,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Arcturus Therapeutics by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company's stock worth $97,000 after acquiring an additional 2,406 shares during the period. Institutional investors and hedge funds own 94.54% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ARCT. HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. William Blair restated an "outperform" rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. Finally, Citigroup lifted their price objective on Arcturus Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, February 8th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $61.33.

Insider Transactions at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 17,435 shares of the firm's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $35.02, for a total transaction of $610,573.70. Following the completion of the sale, the chief operating officer now directly owns 473,448 shares of the company's stock, valued at approximately $16,580,148.96. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 13.80% of the company's stock.

Arcturus Therapeutics Trading Down 1.3 %

Shares of ARCT traded down $0.34 during midday trading on Friday, reaching $25.98. 626,328 shares of the company were exchanged, compared to its average volume of 516,468. Arcturus Therapeutics Holdings Inc. has a 1-year low of $17.52 and a 1-year high of $43.81. The company has a market cap of $699.38 million, a price-to-earnings ratio of -24.98 and a beta of 2.60. The stock has a 50-day moving average price of $34.92 and a 200-day moving average price of $29.73.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The firm had revenue of $33.99 million for the quarter, compared to analyst estimates of $64.14 million. Equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -1.42 earnings per share for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.